Abstract: Some embodiments include methods of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject. Some embodiments include oxygenated fluid for use in treating, inhibiting, or ameliorating ischemic stroke. The oxygenated fluid may comprise charge-stabilized oxygen-containing nanostructures.

Abstract: Some embodiments herein include methods of ameliorating, inhibiting, reducing, treating, slowing the progression of, or preventing a decline in respiratory function associated with a neurological disease of a patient, for example amyotrophic lateral sclerosis (ALS). Some embodiments herein include methods of ameliorating, inhibiting, reducing the symptoms of, treating, slowing the progression of, or preventing a neurological disease of a patient, in which the neurological disease comprises a decline in respiratory function. Some embodiments include methods of deferring an ALS intervention in an ALS patient.

Abstract: Provided are methods for treating pre-neuronal loss abnormalities in synaptic function, comprising administrating to a subject having neurons, an ionic aqueous solution comprising charge-stabilized oxygen-containing nanostructures having an average diameter of less than 100 nm in an amount and for a time period sufficient for preventing or reducing abnormalities in synaptic function that precede neuronal loss and/or NFTs formation in taupathies. Also provided are methods for treating pre-neuronal loss abnormalities in synaptic function, comprising contacting neurons in vitro or ex vivo with an ionic aqueous solution comprising charge-stabilized oxygen-containing nanostructures having an average diameter of less than 100 nm in an amount and for a time period sufficient for preventing or reducing abnormalities in synaptic function that precede neuronal loss and/or NFTs formation.

Abstract: Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing intracellular oxygen delivery or utilization, and/or enhancing ATP synthesis, comprising administration, to a subject in need thereof of a sufficient amount over a sufficient time, of an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures (e.g., nanobubbles) having an average diameter of less than 100 nm (e.g., in at least one subject group selected from but not limited to normal subjects, subjects recovering from neurological trauma (e.g., accidents or injury to the brain, stroke, oxygen deprivation, drowning, and asphyxia), and subjects with learning disorders (e.g.